Physician

Aziz Nicolas Chami, M.D.

According to 2025 Medicare claims, Aziz Chami, M.D. (NPI: 1578672507) practices internal medicine in the Elizabethtown, KY market, with the plurality of this provider's patient population coming from Hardin, KY. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES OF KENTUCKIANA PSC (NPI: 1730161753; TIN: 611141697) and primary practice location at 42701-2537.

Chami's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 825 traditional Medicare patients, billed 4,055 HCPCS/CPT codes, and received $300,942 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,586 prescription claims across 324 beneficiaries totaling $332,178 in drug costs, led by Jardiance (Empagliflozin). 2019 DME data shows 57 claims. Open Payments data shows 60 records totaling $1,212. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $308,544 and ending at $332,178. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,384 to $153.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	836	3,265	$269,270
2016	816	3,086	$276,256
2017	1,114	3,630	$315,524
2018	1,034	3,187	$328,873
2019	956	3,432	$388,365
2020	935	3,390	$355,570
2021	789	2,720	$323,260
2022	716	2,451	$256,958
2023	732	2,446	$249,793
2024	825	4,055	$300,942

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	261	2,566	$308,544
2016	298	2,527	$461,434
2017	389	2,361	$450,133
2018	389	2,430	$296,308
2019	397	2,476	$293,477
2020	383	2,472	$310,949
2021	375	2,459	$374,967
2022	319	1,751	$316,515
2023	318	1,594	$399,663
2024	324	1,586	$332,178

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	65	$10,283
2016	N/R	73	$3,293
2017	N/R	90	$3,930
2018	N/R	71	$9,872
2019	N/R	57	$3,304
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	104	104	$118
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	105	122	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	486	879	$63
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	196	681	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	455	792	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	73	3,630	$71,132
Farxiga	Dapagliflozin Propanediol	77	3,220	$57,061
Auryxia	Ferric Citrate	16	480	$33,715
Kerendia	Finerenone	31	1,170	$24,947
Eliquis	Apixaban	14	1,140	$21,873

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,212	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aziz Nicolas Chami, M.D.?

Tedicare shows public-source Medicare data for Aziz Nicolas Chami, M.D. (NPI 1578672507), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aziz Nicolas Chami, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aziz Nicolas Chami, M.D.?

Aziz Nicolas Chami, M.D. is linked to NEPHROLOGY ASSOCIATES OF KENTUCKIANA PSC (billing NPI 1730161753) in the available physician profile data.

Does Aziz Nicolas Chami, M.D. have Open Payments data?

Aziz Nicolas Chami, M.D. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.